Overview

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Status:
Completed

Trial end date:
2019-08-12

Target enrollment:

Participant gender:

Summary

This trial is conducted globally. The aim of the trial is to investigate efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin background treatment vs. OADs as add-on to metformin background treatment for 104 weeks of treatment in subjects with type 2 diabetes.

Phase:

Phase 4

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

2,4-thiazolidinedione
Dipeptidyl-Peptidase IV Inhibitors
Glycoside Hydrolase Inhibitors
Liraglutide
Meglitinide
Metformin
Sodium-Glucose Transporter 2 Inhibitors